15
Sep
2009
20
Jul
2009
07
Jul
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Immunology, X - Inflammation, X - Metabolism, X - Oncology, XX - MA
Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.
22
Jun
2009
27
May
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, XX - MA
Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.
26
Apr
2009
Posted in I - Series B, Q - 2Q09, R - ROCKY MOUNTAIN, X - Biofuel, X - Metabolism, XX - CO
OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.
30
Mar
2009
Posted in I - Series E, Q - 1Q09, R - NORTH EAST, X - Cardiology, X - Metabolism, XX - MA
Surface Logix (Brighton, MA) a clinical-stage small molecule company focused on metabolic and cardiovascular disease, closed a $15M Series E financing. Participants include ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Co., Unilever Technology Ventures and Venrock.
17
Feb
2009
Posted in I - Series B, Q - 1Q09, R - INTERNATIONAL, X - GI, X - Metabolism
ActoGeniX (Belgium) a clinical-stage biopharmaceutical company focused on the development
of protein therapeutics for the treatment of gastrointestinal and metabolic diseases, closed a $17.1M Series B financing. Participants include Biovest, Gimv, Biotech Fund Flanders, Baekeland Fund, VIB, LSP, Aescap Venture and Ventech.
19
Jan
2009
Posted in I - Series E, Q - 1Q09, R - INTERNATIONAL, X - Cardiology, X - Metabolism, X - Obesity
7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, [...]
05
Dec
2008
Posted in I - Series A, Q - 4Q08, R - WEST, X - Cardiology, X - Inflammation, X - Metabolism
Arete Therapeutics (Hayward, CA) clinical-stage biotechnology company developing soluble epoxide hydrolase inhibitor small molecule drugs for the treatment of cardiovascular, metabolic and inflammatory diseases, closed a $51M Series A financing. Participants include Frazier Healthcare Ventures, Alta Partners, Burrill & Co., Three Arch Partners, and Altitude Life Science Ventures.